Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

Funding Activity in Orthopaedics and Spine

ConforMIS launched $1.8MM offering of warrants to purchase Series D Preferred Stock or other equity securities, received $1.4MM state-funded loan
Proceeds will support expansion of the company’s supply chain and manufacturing presence.
Developing devices that transform traditional CT data into patient-specific implants and instrumentation

Core Essence Orthopaedics completed $11.5MM in Series B Financing
Will support commercialization of devices for soft tissue, skeletal repair

Dallen Medical raised $3.35MM of planned ~$4MM funding round
Will support development, pilot manufacture of Compressyn Band
Technology delivers fixation with compression in sternal closure, small/long bone, spinal, sports med applications

DFine raised ~$15MM of planned $26.5MM funding round
Funds will support clinical studies and launch of the Spinal Tumor Ablation with Radiofrequency system later this year and in early 2012, pipeline projects, sales, etc.

DGIMED ORTHO completed $2.1MM equity financing round; seeking additional $0.4MM
Commercializing system to assist in delivery and distal locking of long bone intramedullary implants

Doctors Research Group raised $7.7MM of planned $15MM financing
Products include bone screw, suture anchor, Kryptonite bone cement for cranial defects, etc.

Ellipse Technologies raised $17.6MM in Series C private equity financing
Will support commercialization of the MAGEC Spinal Deformity System and PRECICE Limb Lengthening System 

Flex Biomedical raised $0.86MM funding
Will support development of Flex Polymer, synthetic injectable therapy for osteoarthritis; plans to commence human clinicals in 2012
Ex-U.S. product launch could commence within 2 years

Graftys received €4MM (~US $5.3MM) in 3rd round of financing
Will support pilot clinical study for combination medical device to address osteoporosis, U.S. commercialization of bone void filler